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Complement C2 receptor inhibitor trispanning (CRIT) is a
novel human complement regulatory cell surface receptor. It
binds the human complement protein C2 and blocks the
classical pathway of complement activation, thus protecting
the cell against complement attack. CRIT expression in the
kidney was analyzed by immunohistochemistry and in situ
hybridization. Normal kidney and renal biopsies of patients
with different nephropathies were studied. In glomeruli, CRIT
protein was expressed only in podocytes. CRIT was also
detected in endothelial cells of arterioles and arteries, but not
of veins and peritubular and glomerular capillaries. A
homogeneous and marked upregulation of CRIT was
observed in podocytes in membranous nephropathy (MN). In
focal and segmental glomerulosclerosis (FSGS) and minimal
change disease, CRIT was downregulated in glomeruli with a
loss of the staining in sclerotic lesions of FSGS. No specific
changes were observed in the other nephropathies studied.
However, podocytes showed in all pathologies a
redistribution of CRIT in the cell bodies of ‘activated’
podocytes. The intensity of mRNA transcription correlated
directly with the protein staining in the normal kidney and in
MN. These data indicate that CRIT is expressed in the normal
human kidney essentially by glomerular podocytes and
arterial endothelial cells. The podocyte CRIT expression is
upregulated in MN, which is in strong contrast with the
known loss of podocyte complement receptor 1. CRIT might
represent the last line of defense against complement
aggression in MN, and the upregulation of CRIT in ‘activated’
podocytes might represent a similar self-defense mechanism.
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The activation of complement and its deleterious conse-
quences have been observed in many acute renal diseases,1
and complement is also thought to accelerate the progression
of chronic renal damage.2–4 Experimental data have demon-
strated the beneficial effects of complement inhibitors in
blocking or reducing renal lesions in many models.5–10
The complement system consists of more than 20 proteins
interacting in a cascade sequence, and may be activated via
the classical, alternative, or lectin pathways.11 The classical
pathway is initiated by the binding of complement
component C1 to the Fc regions of antibody molecules
complexed with antigen. The lectin pathway is activated by
the binding of mannan-binding lectin or ficolins to bacterial
carbohydrates. Both pathways require the assembly of the
C4b2a complex, which then leads to C3 cleavage/activation.
This activation of C3 can then be amplified by the positive
feedback loop of the alternative pathway on pathogens or
surfaces devoid of complement regulatory proteins.
The dual need to effectively destroy pathogens and to
prevent excessive activation on autologous cells and tissues
requires a tight regulation of complement. Complement
regulators include both circulating and cell-bound proteins.
Many soluble proteins in plasma and extravascular fluids
control complement, for example, factor H, which blocks
activation at the C3 and C5 convertases steps. Beside soluble
inhibitors, membrane-bound proteins prevent complement
activation on the cell surface. Several are expressed in the
kidney, and three of these inhibit complement at its most
crucial steps, that is, the formation of the C3/C5 convertases:
(1) in humans, decay-accelerating factor (DAF, CD55) is
expressed in the juxtaglomerular apparatus but only weakly
in the glomeruli;12–14 (2) membrane cofactor protein (MCP,
CD46) is present on many cells in the kidney, in particular
endothelial and mesangial cells in the glomeruli, but not on
podocytes;15,16 (3) interestingly, complement receptor 1
(CR1, CD35), which is on a molar basis the most powerful
inhibitor of the C3 convertases, is expressed only on
podocytes, and to date was the only complement inhibitor
known to be expressed by these cells in humans.17,18 A fourth
regulator, CD59 (protectin) interferes with the insertion of
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the C5b-9 complex in the cell membrane, and is present in
peritubular capillaries, tubular cells, and Bowman’s capsule,
but is expressed at only a low level in mesangial and
endothelial cells in the glomeruli.14,19–21 Although the precise
physiological function of these regulators in the kidney is not
known, they have the potential to interfere with many
biological functions of complement including the release of
C5a (except CD59) and formation of membrane attack
complex. A downmodulation of their expression has been
reported in numerous immune-mediated glomerulopathies
suggesting a loss of protective role against glomerular
damage.12,13,15,22–26
A novel human complement regulatory cell surface
receptor, complement C2 receptor inhibitor trispanning
(CRIT), was first identified on the surface of the Schistosoma
parasite,27 and recently a homologous protein was found in
humans.28 CRIT is a 32 kDa transmembrane protein, with
two extracellular domains (ed1 and ed2), three transmem-
brane, and two intracellular domains.28 In humans, CRIT
binds C2 via the ed1, and by preventing C1s-mediated
cleavage of C2, thus blocks classical pathway activation.29 The
peptide CRIT-H17, an 11-mer synthetic peptide based on the
C-terminal part of the ed1, is able to inhibit efficiently the
formation of the C4b2a convertase in vitro29 and to suppress
immune complex-mediated inflammation in vivo in a mouse
model of the reversed passive Arthus reaction.30
Preliminary data have shown that CRIT is expressed on
many hematopoietic cells, as well as in different tissues
such as testis, tonsil, thymus, liver, and kidney.28 The present
work was undertaken to define the localization of CRIT at
the protein and mRNA levels in the normal kidney, and
to see whether CRIT was modulated in inflammatory
diseases, in particular in immune complex-mediated
glomerulonephritis.
RESULTS
CRIT in normal kidney
CRIT protein was detected exclusively at two locations in the
kidney, the glomeruli and the vessels (Figure 1). In glomeruli,
podocytes were the only cells to express CRIT (Figure 1a and
b). Glomerular endothelial and mesangial cells were negative,
as well as parietal epithelial cells of the Bowman’s capsule.
The specificity of the CRIT localization was confirmed by
immunostaining performed on serial kidney sections using
CR1 and CD31 antibodies, which specifically stain podocytes
and endothelial cells, respectively (Figure 1e–h). In addition
to the podocyte localization, CRIT was detected in endothe-
lial cells of the cortical and medullary arteries, that is, large
and small arteries as well as arterioles (Figure 1i and j). By
contrast, endothelial cells of veins and both glomerular and
peritubular capillaries were not stained (Figure 1i). In the
arteries, a positive staining was detected in the smooth
muscle cells of the media as well (Figure 1i). The other
structures in the cortex and medulla including the interstitial
cells were negative. No glomerular or vascular staining was
detected with preimmune rabbit immunoglobulin (Ig) G or
CRIT antibody preincubated with the ed2 peptide (Figure 1c
and d).
CRIT mRNA transcripts were detected in the same cells
that expressed the CRIT protein, namely in podocytes
(Figure 2) and vascular endothelial and smooth muscle cells
(data not shown). In addition, a slight mRNA transcription
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Figure 1 | Localization of the CRIT protein in normal human
kidney by immunohistochemistry. Specific localization of CRIT
protein in glomerular podocytes (a, b; arrowheads: podocytes) in
comparison with CR1 (podocytes) (e, f) and CD31 (endothelium)
(g, h). Adjacent sections with negative controls: no glomerular
staining detected with preimmune IgG fraction from the rabbit
immunized against CRIT (c) and CRIT antibody preincubated with the
ed2 peptide (d). Localization of CRIT protein in the vessels of the
cortex (i; arrowhead: endothelial cells; black arrow: smooth muscle
cells; white arrow: glomerulus; *: vein) and of the medulla (j) (original
magnification: (a, c–e, g)  100; (b, f, h)  250; (i, j)  25).
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was observed in glomerular parietal epithelial cells and in
some tubular epithelial cells (Figure 2a). The negative control
sense mRNA showed insignificant staining in all cases (data
not shown). In summary, the expression of CRIT in the no-
rmal kidney is limited to podocytes and arterial endothelial
and smooth muscle cells.
CRIT in glomerular diseases
Because of the specific staining of CRIT on glomerular
podocytes, we investigated different types of glomerulopa-
thies (Table 1 and Figures 3 and 4). The glomerular staining
for CRIT was estimated according to a semiquantitative
evaluation performed for each section by two different
pathologists blinded to the study. Compared to normal
staining, three different patterns of abnormal podocyte CRIT
staining were observed: a homogeneous increase (a) or
decrease (b), and a variable and/or inhomogeneous staining
(c) (Table 1 and Figure 4).
(a) A marked increase of the podocyte CRIT staining was
observed in idiopathic membranous nephropathy (MN) (11/
12 cases) (Figure 3a). This upregulated expression was diffuse
and global, with a stronger staining in the cell body of the
‘activated’ or ‘injured’ podocytes, as defined by light and
electron microscopy. The upregulated expression of CRIT
protein in podocytes correlated with an increased transcrip-
tion of CRIT mRNA as detected by in situ hybridization
(Figure 3e and f). Interestingly, the other known complement
inhibitor expressed on podocytes, that is, CR1, was decreased
in MN as previously reported (Figure 3g and h).22 In
addition to the increased podocyte expression, a CRIT
staining was detected in the brush border and in the
cytoplasm of some proximal tubules (Figure 3a). In addition,
there was some mRNA transcription in proximal tubules
(Figure 3e). No staining was detected in glomerular cells
other than podocytes and no modulation of the CRIT
staining was observed in the vessels. This marked increase of
the podocyte CRIT staining was not only observed in
idiopathic MN but also in lupus-associated MN (6/6 cases).
(b) A diffuse downregulation of the podocyte CRIT
staining was seen in focal and segmental glomerulosclerosis
(FSGS), in both affected and unaffected glomeruli (7/7 cases).
A complete loss of the staining was observed in areas of
synechia formation (Figure 3b). CRIT staining was, however,
detected in cell bodies of activated/injured podocytes located
near the sclerotic lesion (Figure 3b). Like in MN, a slight
CRIT staining was detected in the brush border and in the
cytoplasm of some proximal tubules (data not shown). No
modulation of the CRIT staining was observed in the vessels.
Interestingly, in glomeruli with lesions of FSGS secondary to
MN, the loss of the CRIT staining in the sclerotic segments
was concomitant with the increased CRIT staining of the
membranous immune complex-mediated segments (Figure
3c). A similar diminished staining for CRIT was seen in
minimal change disease (4/5 cases) (Figure 3d).
(c) In all other types of glomerulopathies, no distinct
trend in the modulation of the CRIT expression in podocytes
could be defined. Indeed, the semiquantitative analysis of the
CRIT staining varied within glomeruli of the same case and
within cases of the same pathology, with either a normal,
increased, or decreased staining of the podocytes (Table 1 and
Figure 4). This variability of CRIT expression was observed in
immune complex-mediated glomerulonephritis (lupus ne-
phritis of classes II, III, and IV; IgA nephritis) as well as in
non-immune-mediated glomerulopathies (Wegener’s disease,
diabetes, amyloidosis, thrombotic microangiopathy). How-
ever, the one striking qualitative observation was that
‘activated’ and likely injured and enlarged podocytes, as
observed with transmission electron microscopy, stained
strongly for CRIT in all glomerular disease. This staining was
particularly marked for the cell bodies of podocytes. In
contrast, the CRIT staining of endothelial cells was un-
changed in all glomerulopathies studied, including thrombo-
tic microangiopathy. A tubular staining was detected in the
brush border and/or cytoplasm of the proximal epithelial
cells in most glomerulopathies, except in thrombotic
microangiopathy. Finally, in tubulo-interstitial inflammation
associated with glomerulopathies, a CRIT staining was
detected in some inflammatory cells. This interstitial staining
was particularly strong in lupus nephritis.
CRIT in tubulo-interstitial diseases
CRIT staining was analyzed in tubulo-interstitial nephritis
without glomerular lesions and acute tubular necrosis. In
a
b
Figure 2 | Localization of CRIT mRNA in the normal human kidney
by in situ hybridization. (a) Glomerulus; (b) podocyte (arrowheads:
podocytes) (original magnification: (a)  100; (b)  250).
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both, the CRIT expression was not significantly different from
normal kidneys, except for some activated podocytes and
interstitial inflammatory cells, when present.
DISCUSSION
CRIT is a newly described regulator of complement
activation in humans, which blocks classical pathway
activation by binding C2 and inhibiting its cleavage. In the
present study, we show that CRIT expression in the kidney is
localized to very specific cell types. Most striking was the
presence of CRIT confined to the podocytes, an expression
that paralleled that of complement receptor 1 (CD35), a
powerful regulator of the classical and alternative pathway C3
and C5 convertases. CRIT was also detected on endothelial
cells on arteries and arterioles, and in smooth muscles of
arteries. The active local synthesis of CRIT, in the same cells,
was confirmed by the detection of mRNA using in situ
hybridization. It should be mentioned that healthy parts of
kidney material obtained from renal tumors might exhibit
some degree of activation.
Podocytes are highly differentiated cells with a complex
cytoarchitecture.31 From the histochemistry studies, it was
clear that CRIT had a broad distribution on the cell surface
quite similar to CR1. There is no evidence that human
podocytes do express other cell-associated complement
regulators, such as DAF or CD55, membrane cofactor protein
Table 1 | Semiquantitative evaluation of the CRIT staining in
glomerulopathies
Kidney diseases Cases Glomeruli CRIT (1)/(2)
Idiopathic MN 1 6 4.0/4.0
2 5 4.0/4.0
3 2 3.5/3.5
4 15 4.0/4.0
5 12 3.0/3.0
6 21 4.0/4.0
7 15 4.0/4.0
8 16 4.0/4.0
9 11 4.0/4.0
10 21 4.0/4.0
11 17 4.0/4.0
12 12 3.5/4.0
Lupus nephritis 1 (class I/II) 3 2.5/2.5
2 (class II) 8 3.5/3.5
3 (class III) 12 3.5/4.0
4 (class III) 4 4.0/3.5
5 (class IV) 5 4.0/4.0
6 (class IV) 5 4.0/4.0
7 (class V) 6 3.5/3.5
8 (class V) 42 4.0/4.0
9 (class V) 17 4.0/3.5
10 (class V+III) 2 4.0/4.0
11 (class V+III) 1 4.0/4.0
12 (class V+IV) 12 4.0/4.0
FSGS 1 5 2.5/2.0
2 12 2.0/1.5
3 21 2.0/1.0
4 2 2.0/2.0
5 5 2.0/2.0
6 6 1.0/1.0
7 6 1.0/1.0
Minimal change disease 1 10 2.5/2.0
2 10 2.0/2.0
3 2 1.0/1.0
4 3 3.5/2.5
5 9 1.0/1.0
Diabetes 1 4 1.0/1.0
2 11 2.0/1.5
3 8 3.0/2.0
4 7 1.0/1.0
5 4 3.0/2.5
6 7 1.5/2.0
Amyloidosis 1 10 3.5/3.0
2 3 1.0/1.0
3 3 3.5/3.0
4 5 2.0/2.0
Thrombotic microangiopathy 1 6 1.5/1.5
2 3 1.0/1.0
3 6 3.0/3.0
4 12 2.0/2.0
5 5 2.5/2.0
IgA nephritis 1 3 1.0/1.0
2 4 2.0/2.0
3 5 2.5/2.0
4 7 3.5/3.0
5 10 2.0/2.0
6 10 2.5/3.0
Postinfectious nephritis 1 8 1.5/1.5
Table 1 | Continued
Kidney diseases Cases Glomeruli CRIT (1)/(2)
2 5 1.5/1.5
Wegener’s disease 1 7 2.0/2.0
2 7 3.5/3.0
3 2 3.0/2.5
4 10 1.5/1.5
5 7 3.0/3.0
6 3 4.0/4.0
7 6 3.0/3.0
Tubulo-interstitial nephritis 1 2 2.5/2.0
2 2 1.5 /1.5
3 8 3.5/2.5
4 3 1.5/1.5
5 3 4.0/3.0
Acute tubular necrosis 1 5 2.0/2.0
2 10 3.0/3.0
3 10 2.0/2.5
Alport’s syndrome 1 5 2.0/2.0
Thin membrane disease 1 15 4.0/4.0
CRIT, complement C2 receptor inhibitor trispanning; FSGS, focal and segmental
glomerulosclerosis; IgA, immunoglobulin A; MN, membranous nephropathy.
Two different pathologists ((1) and (2)) blinded to the study evaluated each
glomerulus of all the sections according to a predefined grading scale: Grade
3=normal staining (100%); Grade 4=increase of the staining (4100%); Grade
2=moderate decrease of the staining (o100%, 450%); Grade 1=severe decrease of
the staining (o50%, 410%); Grade 0=loss of the staining (o10%). The normal
staining was defined according to the staining of the normal renal tissue. A mean
score of glomerulus intensity was obtained for each section rounded to half grade
(0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4).
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(MCP or CD46), or CD59. This very specific distribution of
complement regulators in the glomerulus and particularly in
podocytes might correspond to defined protection mechan-
isms. In mice, it has been shown using knockout animals that
CD59 and DAF protect the glomerulus from immune
complex damage in acute nephrotoxic nephritis.32 Whereas
CD59 limits the cell-mediated damage induced by C5b-9,
DAF appears to be essential to prevent (or diminish) the
injury induced by autoantibodies activating the classical
pathway.32,33 Particularly relevant to the present work is that
in rats, DAF is expressed mainly by podocytes and has
functionally been shown to be a powerful inhibitor of
classical pathway activation.33 Although totally different in
structure and activity, CRIT is located in humans on the
same cells and has also the potential to block classical
pathway function, although the functional activity of CRIT
on podocytes remains to be demonstrated. Thus, it appears
that podocytes possess different complement regulators in
different species, but that podocytes are always in a position
to control complement. The combined expression of CRIT
and CR1 in human podocytes should compensate for the
absence (or poor) expression of other complement inhibi-
tors, and allow them to resist complement attack.
When CRIT was analyzed in different types of glomerular
disease, it was apparent that podocytes were expressing an
increased amount of CRIT in MN. This overexpression was
specific, as it was not present in other glomerular diseases,
and was due to increased synthesis of the protein as judged by
enhanced transcription of CRIT mRNA. This increased
podocyte expression was observed in both idiopathic and
lupus-associated MN. It contrasted with the loss of CR1 as
observed previously.22 MN is characterized by the deposition
of immune complexes on the epithelial side of the glomerular
basement membrane. Heymann nephritis is a good model for
MN. This model together with recent evidence obtained in
neonatal MN suggests strongly that the formation of immune
complexes occurs locally.34 These immune complexes trigger
complement activation, which is to a large degree responsible
for heavy proteinuria. Others have shown in a rat model of
passive Heymann nephritis that the complement regulators
Crry and CD59 of podocytes play an important role in
restraining complement-mediated injury following sube-
pithelial immune complex formation.35 As reviewed by
Mathieson,36 in MN the deposition of immune complexes
in the subepithelial space directly adjacent to the podocytes is
responsible for podocyte damage. The local activation of
complement is highlighted by the presence of C5b-9
complexes locally, as well as in urine.37 The insertion of
C5b-9 in the podocyte cell membrane induces cell activation
and signal transduction, with increased production of
oxidants leading to glomerular basement membrane damage
and proteinuria.38,39 It is thus likely that the presence of
a b
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Figure 3 | CRIT modulation in different types of glomerulopathy.
CRIT protein modulation in MN (a; arrowhead: brush border of
proximal tubule), FSGS (b; arrowhead: activated podocyte with
intracytoplasmic vacuoles; arrow: FSGS lesion), MN with secondary
FSGS (c; arrow: FSGS lesion) and minimal change disease (d). CRIT
mRNA modulation in MN (e and f; arrowheads: podocytes).
Comparison with CR1 protein modulation (g: normal glomerulus;
h: membranous nephropathy) (original magnification: (a–e, g, h)
 100; (f)  250).
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Figure 4 | Semiquantitative evaluation of the CRIT staining in
glomerulopathies. Average scores for the different diseases are
listed in Table 1.
Kidney International (2006) 69, 1961–1968 1965
S Moll et al.: CRIT expression in human kidney o r i g i n a l a r t i c l e
CRIT in humans at this strategic site may play a role in trying
to control activation of complement, but that this regulatory
capacity is overwhelmed in many patients with MN. The
increased synthesis and transcription of CRIT could be
understood as a tentative counter-measure by the cell to
prevent too severe damage by competing with the surface-
bound C4b for C2. This protection mechanism might be
essential in MN, as the only other complement regulator
expressed by podocytes, namely CR1, is downregulated.
There are, however, no data yet to demonstrate that CRIT is
functional in MN.
In contrast with the upregulation of CRIT on podocytes in
MN, a decreased expression of CRIT protein was demon-
strated in most podocytes of FSGS. This downregulation, in
correlation with the decrease of CR1,22 could be part of the
dysfunctioning podocyte, which is now considered as the
starting event in FSGS.40 The complete loss of CRIT staining
observed in the areas of synechia formation in FSGS is not
surprising, as these areas are characterized by a loss of
podocytes.40 Another interesting observation concerns sec-
ondary FSGS. In contrast to primary FSGS, where a global
downregulation of podocyte CRIT staining was observed, the
CRIT expression in secondary FSGS might reflect the
underlying glomerulopathy: indeed, as demonstrated in
FSGS secondary to MN, CRIT staining was, as expected,
absent within the sclerotic segments, but increased within the
segments with epithelial immune complex deposition. This
observation indicates a high selectivity in the mechanisms
inducing CRIT expression.
In other types of glomerulopathies, no clear trend of CRIT
modulation could be defined. Indeed, CRIT expression was
inhomogeneous within the cases of the same pathology and
within the glomeruli of the same case. However, it was
particularly noteworthy that a heavy staining was detected in
cell bodies of ‘activated’ podocytes independently of the type
of underlying glomerular lesions (including FSGS). Activated
podocytes are characterized by morphological alterations,
such as increased intracytoplasmic organelles, vacuole
formation, and microvilli formation.41 These ultrastructural
modifications might reflect a modification of the metabolism
and/or cellular activity of the podocytes. Although no
electron microscopy immunostaining was performed, acti-
vated podocytes were identified here by their large body size
and the presence of vacuoles. The striking increase of CRIT in
such cells suggests that upregulation of CRIT belongs to the
program of ‘activated’ podocytes.
Endothelial cells of arteries and arterioles in the normal
kidney express CRIT; however, no other endothelial cells did
so. Interestingly, expression of CRIT in the various diseases
studied did not change significantly even in thrombotic micro-
angiopathies. Finally, proximal tubular epithelial cells express
CRIT mRNA, both in the normal kidney and in MN; however,
it was not possible to quantitate this expression. The in-
creased staining CRIT protein observed in the brush border
and/or cytoplasm of the proximal epithelial cells in most
glomerulopathies might reflect increased local synthesis,
or a (re)absorption of CRIT released by podocytes in the urine,
either as free molecules or part of podocyte vesicles as recently
described by Hara et al.42
In summary, with this study, we confirmed that CRIT is
constitutively expressed in the normal kidney in podocytes
and endothelial and smooth muscle cells of arterial vessels.
We demonstrated, with the analysis of different types of
glomerulopathies, that CRIT expression is increased in
podocytes of MN, and in ‘activated’ podocytes in other
diseases. Whether the increase of CRIT is only a marker of
injured podocytes or contributes to protect glomeruli has yet
to be investigated.
MATERIALS AND METHODS
Antibodies
The presence of CRIT was assessed using an affinity-purified
polyclonal rabbit anti-human CRIT antibody, which is directed
against the CRIT-ed2.28
Monoclonal anti-human antibodies, directed against CR1
(MAB543, kindly provided by Dr Christian Drouet), which is
expressed exclusively in podocytes,22 and monoclonal anti-human
CD31 antibodies, directed specifically against endothelial cells
(DakoCytomation, Glostrup, Denmark), were used on serial
sections in normal kidney.
Kidney biopsies
Seventy-seven renal biopsy specimens taken between 2001 and 2005
were selected from the files of the Departments of Pathology,
University Hospitals of Geneva, Lausanne and Basel. Normal renal
tissue was obtained from normal parts of four nephrectomies
performed for renal cell carcinoma. Several different diseases were
studied: 12 idiopathic MN, six IgA glomerulonephritis, 12 lupus
nephritis (two class II according to the WHO classification, two class
III, two class IV, and six class V), two post-infectious glomerulo-
nephritis, seven Wegener’s disease, seven FSGS, five minimal change
disease, six diabetes, four amyloidosis, five thrombotic microangio-
pathy, one Alport’s syndrome, one thin membrane disease, five
tubulo-interstitial nephritis, and four acute tubular necrosis. For all
biopsy specimens, standard analysis using light microscopy,
immunofluorescence (Ig and complement C3 and C5b-9 deposits),
and electron microscopy was performed.
Immunohistochemical procedures
Histological sections (3 mm) were obtained from formaldehyde-fixed
paraffin-embedded biopsies. These were deparaffinized and then
endogenous peroxidase was blocked with 0.3% H2O2 in methanol
for 30 min. The sections were digested with 0.05% proteinase K in
phosphate-buffered saline for 2 min, and incubated with the
primary polyclonal rabbit anti-human CRIT-ed2 antibody at a
1:100 dilution overnight at 41C. Then, they were incubated with a
biotinylated goat anti-polyvalent antibody (Vectastain Elite ABC Kit
Universal, Vector, Burlingame, CA, USA) for 30 min at room
temperature, washed and incubated with ABC reagent for 30 min.
For detection, the liquid diaminobenzidine substrate-chromogen
system (DakoCytomation) was used according to the manufacturer’s
instructions. Counterstaining was performed using hematoxylin
Mayer, and dehydration by using decreasing alcohol concentrations.
Stained sections were mounted with permanent mounting medium
(Eukitt, Electron microscopy sciences, Hatfield, PA, USA) and the
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tissues were examined with a Zeiss microscope (Zeiss, Oberkochen,
Germany).
Adjacent sections of normal renal tissue were incubated with
anti-CR1 or anti-CD31 monoclonal antibodies. Negative controls
included adjacent sections of normal renal tissue incubated with
preimmune IgG fraction from the rabbit immunized against CRIT,
CRIT antibody preincubated with the ed2 peptide, bovine serum
albumin, and buffer alone.
In situ hybridization
A polymerase chain reaction product representing the first 489 bp of
human CRIT cDNA (GenBank AY 464186) was cloned into a
pcDNA3.1 (þ /) expression vector (Invitrogen, San Diego, CA,
USA). The vector was linearized enzymatically with NotI or HindIII,
followed by phenol extraction and precipitation under RNAse free
conditions. Run-off digoxigenin (DIG) labeled sense and antisense
mRNA transcripts were transcribed using SP6 and T7 RNA
polymerase according to the manufacturer’s instructions (DIG
RNA Labeling Kit, Roche, Basel, Switzerland).
In situ hybridization was adapted from a method described by
Lange et al.43 All solutions were treated with 0.1% diethyl
pyrocarbonate (Sigma-Aldrich, St Louis, MO, USA) and autoclaved
before use. In brief, paraffin-embedded sections were deparaffinized,
washed, and rehydrated through a graded series of ethanol. The
sections were postfixed in 4% paraformaldehyde in Tris-buffered
saline (TBS) for 10 min at 41C, washed in TBS, and digested with
30 mg/ml proteinase K in TE buffer for 30 min at 371C. After
washing in TBS, the digestion was stopped by incubating the
sections in TBS at 41C for 5 min. The sections were prehybridized in
4 SSC (standard sodium citrate) and 50% formamide (Sigma) for
15 min at 401C. The probes were diluted in hybridization buffer
(4 SSC, 40% formamide, 10% dextran sulfate, 1 Denhardt’s
solution, 1 mg/ml yeast tRNA (Roche), 50 mg/ml heparin (Sigma),
10 mM dithiothreitol) and incubated at 651C for 7 min before adding
to the sections. The sections were then incubated overnight at 401C.
After incubation, any unbound probe was washed off at 371C with
2 SSC for 2 15 min, 1 SSC for 2 15 min and at room
temperature in 0.1 SSC for 2 30 min. The sections were then
washed in TBS and blocked in 2% blocking reagent (Roche) in TBS
for 30 min at room temperature followed by incubation for 2 h at
room temperature with anti-DIG-AP Fab fragments (Roche) diluted
1/400 in 2% blocking reagent in TBS. Then, the sections were
washed in TBS and color detection was performed with fast red
(DakoCytomation). The sections were background stained with
Mayer’s hematoxylin (Sigma) and mounted with Faramount
(DakoCytomation). Negative controls included adjacent sections
of normal renal tissue incubated with sense mRNA probe.
Semiquantitative analysis of the staining intensity
All evaluations of the glomerular staining intensities were performed
semiquantitatively by two different pathologists blinded to the
study. All glomeruli of each slide were evaluated according to a
predefined grading scale: Grade 3, defined as a normal staining
according to the staining of the normal renal tissue (100%); Grade 4,
defined as a marked increase of the staining (4100%); Grade 2,
defined as a moderate decrease of the staining (o100%, 450%);
Grade 1, defined as a severe decrease of the staining (o50%,
410%); and Grade 0, defined as an almost complete absence of the
staining (o10%). A mean score of glomerular intensity was
obtained for each section.
The glomerular distribution of the staining was evaluated as well.
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